A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination

International Archives of Allergy and Immunology

Volumn 142, Issue 4, 2007, Pages 274-284

  Bonura, A ^a   Corinti, S ^c   Artale, A ^a   Di Felice, G ^c   Amoroso, S ^b   Melis, M ^a   Geraci, D ^a   Colombo, P ^a  

^a CNR Consiglio Nazionale delle Ricerche   (Italy)

^b Ospedale Civile Di Vicenza   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Allergy vaccination; Parietaria pollen; Recombinant allergens

Indexed keywords

POLLEN ANTIGEN;

ALLERGY; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONTROLLED STUDY; DISULFIDE BOND; DNA RECOMBINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOGENICITY; MEDICAL TECHNOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARIETARIA; PERIPHERAL BLOOD MONONUCLEAR CELL; POLLEN; PRICK TEST; PRIORITY JOURNAL; SENSITIZATION; SERUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; WESTERN BLOTTING;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; ESCHERICHIA COLI; FEMALE; HISTAMINE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; LEUKOCYTES; MICE; MICE, INBRED BALB C; PARIETARIA; PLANT PROTEINS; POLLEN; RECOMBINANT PROTEINS; SKIN TESTS; VACCINATION;

EID: 33947275894     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097358     Document Type: Article

References (35)

1. D'Amato G, Liccardi G, D'Amato M, Cazzola M: The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy. Respir Med 2001;95:606-611.
2. Turner H, Kinet JP: Signalling through the high-affinity IgE receptor FcεRI. Nature 1999;402:B24-B30.
3. van der Heijden FL, Joost van Neerven RJ, van Katwijk M, Bos JD, Kapsenberg ML: Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993;150:3643-3650.
4. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-562.
5. Secrist H, DeKruyff RH, Umetsu DT: Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995;181:1081-1089.
6. Akdis CA, Blesken T, Wymann D, Akdis M, Blaser K: Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants. Eur J Immunol 1998;28:914-925.
7. Wachholz PA, Soni NK, Till SJ, Durham SR: Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003;112:915-922.
8. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, et al: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-1208.
9. Ball T, Sperr WR, Valent P, Lidholm J, Spitzauer S, Ebner C, Kraft D, Valenta R: Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999;29:2026-2036.
10. Flicker S, Valenta R: Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003;132:13-24.
11. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J, Ipsen H: Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:2944-2952.
12. Kepley CL, Cambier JC, Morel PA, Lujan D, Ortega E, Wilson BS, Oliver JM: Negative regulation of FcεRI signaling by FcγRII co-stimulation in human blood basophils. J Allergy Clin Immunol 2000;106:337-348.
13. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T: Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002;57:423-430.
14. Linhart B, Valenta R: Molecular design of allergy vaccines. Curr Opin Immunol 2005;17:646-655.
15. Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, Konig F, Valenta R, Niederberger V: Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347-354.
16. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:4187-4194.
17. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, Reisinger J, Pelzmann M, Hayek B, Kronqvist M, et al: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004;101(suppl 2):14677-14682.
18. D'Amato G: Urban air pollution and plant-derived respiratory allergy. Clin Exp Allergy 2000;30:628-636.
19. D'Amato G, Spieksma FT, Liccardi G, Jager S, Russo M, Kontou-Fili K, Nikkels H, Wuthrich B, Bonini S: Pollen-related allergy in Europe. Allergy 1998;53:567-578.
20. Costa MA, Colombo P, Izzo V, Kennedy H, Venturella S, Cocchiara R, Mistrello G, Falagiani P, Geraci D: cDNA cloning, expression and primary structure of Par j I, a major allergen of Parietaria judaica pollen. FEBS Lett 1994;341:182-186.
21. Duro G, Colombo P, Assunta Costa M, Izzo V, Porcasi R, Di Fiore R, Locorotondo G, Cocchiara R, Geraci D: Isolation and characterization of two cDNA clones coding for isoforms of the Parietaria judaica major allergen Par j 1.0101. Int Arch Allergy Immunol 1997;112:348-355.
22. Duro G, Colombo P, Costa MA, Izzo V, Porcasi R, Di Fiore R, Locorotondo G, Mirisola MG, Cocchiara R, Geraci D: cDNA cloning, sequence analysis and allergological characterization of Par j 2.0101, a new major allergen of the Parietaria judaica pollen. FEBS Lett 1996;399:295-298.
23. Colombo P, Bonura A, Costa M, Izzo V, Passantino R, Locorotondo G, Amoroso S, Geraci D: The allergens of Parietaria. Int Arch Allergy Immunol 2003;130:173-179.
24. Poznanski J, Sodano P, Suh SW, Lee JY, Ptak M, Vovelle F: Solution structure of a lipid transfer protein extracted from rice seeds. Comparison with homologous proteins. Eur J Biochem 1999;259:692-708.
25. Bonura A, Amoroso S, Locorotondo G, Di Felice G, Tinghino R, Geraci D, Colombo P: Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the non-specific lipid transfer protein plant family. Int Arch Allergy Immunol 2001;126:32-40.
26. Orlandi A, Grasso F, Corinti S, Marinaro M, Bonura A, Boirivant M, Colombo P, Di Felice G: The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin Exp Allergy 2004;34:470-477.
27. Cocchiara R, Di Trapani G, Azzolina A, Albeggiani G, Geraci D: Identification of a histamine-releasing factor secreted by human pre-implantation embryos grown in vitro. J Reprod Immunol 1988;13:41-52.
28. Stumvoll S, Westritschnig K, Lidholm J, Spitzauer S, Colombo P, Duro G, Kraft D, Geraci D, Valenta R: Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 2003;111:974-979.
29. Colombo P, Kennedy D, Ramsdale T, Costa MA, Duro G, Izzo V, Salvadori S, Guerrini R, Cocchiara R, Mirisola MG, et al: Identification of an immunodominant IgE epitope of the Parietaria judaica major allergen. J Immunol 1998;160:2780-2785.
30. D'Amato G, Cocco G, Liccardi G, Melillo G: A study on airborne allergenic pollen content of the atmosphere of Naples. Clin Allergy 1983;13:537-544.
31. Amoresano A, Pucci P, Duro G, Colombo P, Costa MA, Izzo V, Lamba D, Geraci D: Assignment of disulphide bridges in Par j 2.0101, a major allergen of Parietaria judaica pollen. Biol Chem 2003;384:1165-1172.
32. Akdis CA, Blaser K, Akdis M: Genes of tolerance. Allergy 2004;59:897-913.
33. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA: Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;97:1356-1365.
34. Vrtala S, Hirtenlehner K, Susani M, Akdis M, Kussebi F, Akdis CA, Blaser K, Hufnagl P, Binder BR, Politou A, et al: Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001;15:2045-2047.
35. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, Valenta R: Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002;16:1301-1303.